Compare TK & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | JANX |
|---|---|---|
| Founded | 1973 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | 108 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 847.1M |
| IPO Year | 1995 | 2021 |
| Metric | TK | JANX |
|---|---|---|
| Price | $13.47 | $14.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 446.5K | ★ 870.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $12.12 |
| 52 Week High | $14.38 | $35.34 |
| Indicator | TK | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 43.52 |
| Support Level | $12.09 | $13.88 |
| Resistance Level | $13.76 | $14.44 |
| Average True Range (ATR) | 0.50 | 0.55 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 39.74 | 37.35 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.